OAIC

MISSION STATEMENT:

The overall goal of the Pepper Study Registry (PSR) is to guarantee the proper and long-term access to, preservation and management of data resources to be used for conducting future studies by investigators with an interest in aging-related research.

The PSR provides meta-data for self-deposited aging studies from Pepper Older American Independence Centers (OAICs).
The PSR provides data resources to the Designated Community (researchers and practitioners related to aging) by curating, preserving, and disseminating raw data that are deposited into the repository.

PSR WORKFLOW:

Download to read full details on the PSR Workflow

PSR DATA INTEGRITY & AUTHENTICITY:

Describes the policy for data integrity and authenticity for the PSR. Data integrity and authenticity is managed within the PSR system as part of the processes for data deposit, database change management, and data access. The integrity and authenticity of the data also is recorded as part of the documentation of changes to the data.
Download to read full details on PSR Data Integrity and Authenticity

PSR DATA PRESERVATION POLICY:

Describes the PSR's data preservation policy to the data depositors and users of the PSR. The PSR follows the general functions for data preservation described by the Open archival information system (OAIS) framework [1], including data ingest, storage, management, access, dissemination, and migration. The PSR recognizes the varying levels of responsibility in preserving each deposited item. Therefore, this policy of the PSR preservation plan is made available to all PSR staff and to the users of the PSR.
Download to read full details on the PSR Data Preservation Statement

PSR REVIEW COMMITTEE:

The PSR Review Committee includes a body of experts, both intramural and outside of the institution (Wake Forest University School of Medicine) for providing technical review and consultation for the PSR. The goal is to ensure that the PSR is up to date on compliance with principles for a standard, modern data registry and repository.
Download to read full details on the PSR Review Committee

PSR CONTINUED SUPPORT:

Link to NIA RePORTER

Contact the Registry Coordinator at (336) 713-7126 or PepperCenter@WakeHealth.edu for additional information.

How to search: Enter any single word, or combination of words using " + " (space plus space) in between. As an example, to search for both male and female with a condttion of obesity that have DEXA, enter "DEXA + Obesity + M/F". Clicking a column header will sort the data by that column's data.
Notes: Most studies will have some available demographic and many will have laboratory data. An asterisks (*) indicate study collected by not available in the database.

Study (PI)	Gender	Age	Disease/ Condition	N=	Design / Intervention	Biospecimen	Imaging	Physical	Activity Monitoring	Cognitive / Depression
Functional near-infr... (Huppert, Pittsburgh)	M / F			19	cross-sectional cohort					DSST Stroop
This study measured ... (Hergenroeder, Pittsburgh)	M / F	69 -98		43	cross-sectional cohort				ActivPAL
7 activity monitors ... (Hergenroeder, Pittsburgh)	M / F	69 -98		43	cross-sectional cohort				Actigraph (Wrist) Actigraph (Hip) ActivPAL Fitbit
ADAPT (Messier, WFU)	M / F	60 +	knee osteoarthritis	316	exercise / diet 18 mos			Gait Speed PAT-D		MMSE CES-D
AML (Klepin, WFU)	M / F	60 +	AML	81	Parallel Assignment 24 weeks			Grip Strength SPPB PAT-D Knee Extensor		3MSE CES-D
APPLE (Nicklas, WFU)	M / F	65 -79	Arthritis, OA, weight loss	40	weight loss: no vest vs weighted vest 22 weeks	Serum Plasma Adipose	DEXA	Gait Speed ESPPB Leg Press Knee Extensor		MoCA CES-D
Bicarb (Petrovic, WFU)	M / F	65 +	Kidney disease / disability	80	3 months RCT oral bicarbonate supplement vs placebo	Serum Plasma Urine	DEXA	Gait Speed SPPB		MoCA
BRJS (Miller, WFU)	M / F	60 -84		27	randomized, double blind, placebo-controlled trial	Plasma	CT DEXA	Gait Speed Knee Extensor
CLIP (Rejeski, WFU)	M / F	60 -79	Overweight/obese; CVD or METs	288	18-month RCT Caloric Restriction and/or Aerobic Exercise	Serum Plasma	DEXA	Gait Speed SPPB PAT-D
CLIP II (Rejeski, WFU)	M / F	60 -79	cardiovascular disease	252	Weight Loss alone, aerobic exercise training +Weight Loss or resistance exercise training +Weight Loss 18 mos		DEXA *	SPPB * Knee Extensor *	Actigraph (Hip) *
COCOA-PAD II (McDermott, NW)	M / F	55 +	Peripheral artery disease	190	RCT cocoa flavanols	Serum Plasma DNA	MRI	Gait Speed SPPB CPET	Actigraph (Hip)	MMSE
DEMO (Nicklas, WFU)	F	50 -70	Abdominal obesity	112	5-month RCT Caloric Restriction vs. CR + Aerobic Exercise	Serum Plasma Adipose DNA	DEXA	Grip Strength SPPB PAT-D		MMSE CES-D
EFFECT - Pilot (Morris, WFU)	M / F	18 +	ICU patients	100	Cross-sectional Intensive physical therapy vs. Usual Care	Serum Plasma DNA
EMPOWER (Nicklas, WFU)	M / F	65 -85	Obesity	189	Randomized to 3 treatment arms 18 mos	Serum Plasma	DEXA	Gait Speed Grip Strength ESPPB	ActivPAL *	DSST MoCA CES-D
EVIDENCE (Houston, WFU)	M / F	65 +	Vitamin D Insufficient	200	Vitamin D vs Placebo 12 month	Serum Muscle		Gait Speed Grip Strength SPPB ESPPB Leg Press Knee Extensor CHAMPS Postural Sway Gait Rite		DSST MoCA Story Recall * CES-D
EVIDENCE Sub Study (Molina, WFU)	M / F	65 +	Vitamin D Insufficient	40	Vitamin D & Muscle Function 4 months	Serum Plasma		Gait Speed Grip Strength SPPB ESPPB Leg Press		MoCA
FIT (F/U Infinite) (Nicklas, WFU)	M / F	65 -80	obesity, follow up to INFINITE Study	0	18 mos	Plasma DNA		Gait Speed ESPPB CHAMPS *		DSST MMSE CES-D
FLOW (Hundley, WFU)	M / F	50 +	Aging/Heart Failure	30	Cross-sectional N/A	Serum Plasma		Grip Strength SPPB PAT-D
GIFT II (McDermott, NW)	M / F	55 +	Peripheral artery disease	30	RCT unacylated ghrelin	Serum Plasma DNA	MRI	Gait Speed SPPB CPET		MMSE
GO MET (Ding, WFU)	M / F	65 -79	CAD / Cancer / MCI / Physcial Function Decline	30	Crossover Metformin vs Placebo 24 months	Serum Plasma DNA		Gait Speed Grip Strength ESPPB PAT-D Leg Press Knee Extensor *		DSST MoCA
Healthy Aging (Kitzman, WFU)	M / F	60 +	Healthy controls	61	Cross-sectional N/A	Serum Plasma Urine Muscle DNA	DEXA	Gait Speed Grip Strength SPPB PAT-D Leg Press Knee Extensor CHAMPS	ActivPAL *	MMSE Rey AVLT * Trail Making *
HI-PAD (McDermott, NW)	M / F	55 +	Peripheral artery disease	39	RCT VM202	Serum Plasma DNA	CT MRI	Gait Speed SPPB CPET		MMSE
HOPE - Pilot (Houston, WFU)	M / F	55 +	Obesity	54	Exercise Study Follow up / Feasibility Study n/a		DEXA	Gait Speed Grip Strength ESPPB Leg Press Knee Extensor *		DSST * MoCA Rey AVLT * TICS * Trail Making * CES-D *
I'M FIT (Nicklas, WFU)	M / F	65 -79	Obese; at risk for disability	130	5-month RCT Resistance Training (RT) vs. Resistance Training (RT) + Caloric Restriction	Serum Plasma Muscle Adipose	CT DEXA	Gait Speed Grip Strength SPPB ESPPB PAT-D Leg Press Knee Extensor		MMSE
IDEA (Messier, WFU)	M / F	55 +	Overweight/obese; Knee OA	450	18-month RCT Caloric Restriction vs. Aerobic Exercise vs. CR+AEX	Serum Plasma Urine DNA	CT DEXA	Gait Speed Grip Strength SPPB PAT-D Leg Press	ActivPAL *	DSST MMSE 3MSE CES-D
INFINITE (Nicklas, WFU)	M / F	65 -79	Obese	180	5-month RCT Aerobic Exercise vs AEX + Hi Caloric Restriction vs AEX + Low Caloric Restriction	Serum Plasma Adipose DNA	DEXA	Gait Speed SPPB PAT-D	RT3 *	DSST MMSE Rey AVLT * COWA * Stroop * CES-D
INTERCEDE (McDermott, NW)	M / F	55 +	Peripheral artery disease	230	RCT Intermittent Pneumatic Compression (IPC) with and without exercise	Serum Plasma DNA	MRI	Gait Speed SPPB CPET	Actigraph (Wrist)	MMSE Stroop
LEAN (Nickals, WFU)	M / F		Obesity	0		Serum Plasma Muscle	CT DEXA	Gait Speed Grip Strength ESPPB PAT-D Leg Press Knee Extensor		MMSE
LIFE - Pilot (Kritchevsky, WFU)	M / F	70 -89	At risk for disability	424	12-month RCT Aerobic + Resistive Exercise vs. Control	Serum Plasma DNA	DEXA *	Gait Speed Knee Extensor *		CES-D *
LOSE-IT (Miller, WFU)	M / F	18 +	Bariatric surgery patients	42	Cross-sectional N/A	Serum Plasma Muscle Adipose	CT DEXA	SPPB PAT-D Knee Extensor *		CES-D
MAT-PAC (Kim, WFU)	M / F	65 +	Mobility	0	observational
Medifast (Beavers, WFU)	M / F	65 -79	Obesity	124	Weight Loss (High Protein Group) / Weight Stable group 24 mos	Serum Plasma Urine	DEXA *	Gait Speed Grip Strength ESPPB PAT-D Leg Press	Actigraph (Wrist) *	DSST MoCA CES-D
MidCog (Wolf, NW)	M / F	40 -64		1200	observational longitudinal cohort study N/A			Gait Speed Grip Strength	Actigraph (Wrist)	MoCA Story Recall
MORPH (Brooks, WFU)	M / F	55 -85	Obesity / Pain	35	(2) a two group randomized controlled pilot trial (RCT) in 35 obese (BMI=30-45 kg/m2), low-active, older (55-85 years) adults with chronic pain randomized to either 12-weeks of active intervention or a wait-list control. 12 weeks			ESPPB		MoCA CES-D
MOW Vitamin D (Houston, WFU)	M / F	65 +	Vitamin D Insufficient	68	100,000 IU OF VITAMIN D VS PLACEBO (400 IU VIT E) AND FALLS ASSESSMENT 5 month Randomized Control Trial	Serum Plasma		PAT-D
NICE (McDermott, NW)	M / F	18 +	Peripheral artery disease	90	RCT Nicotinamide riboside, resveratrol	Serum Plasma DNA		Gait Speed SPPB CPET		MMSE
OPTIFAST (Ard, WFU)	M / F	64 +	Obesity / Disability	88	high intensity weight loss protocol VS a moderate intensity weight loss protocol 26 weeks		DEXA	Gait Speed ESPPB Knee Extensor		DSST MoCA
OPTIMA (Kritchevsky, WFU)	M / F	65 -79	Overweight/obese; at risk for disability	88	6-month RCT Caloric Restriction + Pioglitazone vs. CR + Resistance Exercise	Serum Plasma Muscle	CT DEXA	Gait Speed Grip Strength SPPB ESPPB PAT-D Leg Press Knee Extensor * CHAMPS		MMSE CES-D
PA AML (Klepin, WFU)	M / F	60 +	Acute Myeloid Leukemia	70	Interventional Clinical Trial Parallel Assignment			Grip Strength SPPB PAT-D		DSST CES-D
PACT (Miller, WFU)	M / F	60 +	Overweight/obese; Knee OA	84	6-month RCT Caloric Restriction + Exercise vs. Control	Serum Plasma Muscle DNA	DEXA	Gait Speed PAT-D *
PAIN (Brooks, WFU)	M / F	65 +	chronic pain	33	observational 3 months			SPPB PAT-D
PART - Transplant (Hartmann, WFU)	M / F	60 +	Renal Transplant	30	physical activity 3 months	Serum Urine	DEXA	Gait Speed Grip Strength SPPB PAT-D Leg Press CHAMPS	Actigraph (Hip) *	MMSE CES-D
PERMET (McDermott, NW)	M / F	18 +	Peripheral artery disease	212	RCT metformin	Serum Plasma DNA		Gait Speed SPPB CPET		MMSE
PIE (Kitzman, WFU)	M / F	60 +	Diastolic heart failure	80	12-month RCT ACE inhibitor use vs Placebo	Serum Plasma Muscle DNA	DEXA	Grip Strength SPPB PAT-D
PIE II (Kitzman, WFU)	M / F	60 +	Diastolic heart failure	80	12-month RCT Spironolactone vs Placebo	Serum Plasma Muscle DNA	DEXA	Grip Strength SPPB PAT-D
POWER (Marsh, WFU)	M / F	65 +	At risk for disability	45	3-month RCT Strength training vs. Power training vs. Control	Serum Plasma Muscle	DEXA	SPPB PAT-D		CES-D
PREDICT (Hundley, WFU)	M / F	55 -85	At risk for CHF	608	Longitudinal cohort N/A	Serum DNA	MRI	Gait Speed Grip Strength SPPB PAT-D Leg Press
PROVE (McDermott, NW)	M / F	18 -90	Peripheral artery disease	212	RCT Weight loss, Exercise	Serum Plasma DNA		Gait Speed SPPB CPET	Actigraph (Wrist)	MMSE
RAINS (Kritchevsky, WFU)	M / F	65 -85	Overweight/obese; at risk for disability	67	4-month intervention Nutrition (protein) supplementation	Serum Plasma
REACT II (Berry, WFU)	M / F	37 -95	COPD	200	12-month RCT Aerobic Exercise	Serum Plasma DNA	DEXA	Grip Strength SPPB PAT-D Knee Extensor *		CES-D
REACT III (Berry, WFU)	M / F	45 -80	COPD	32	4-month RCT Resistance Exercise vs. Control	Serum Plasma Muscle DNA
SECRET (Kitzman, WFU)	M / F	60 +	Overweight/obese; heart failure	100	5-month RCT Caloric Restriction vs. Aerobic Exercise vs. CR+AEX	Serum Plasma Muscle DNA	DEXA	Gait Speed Grip Strength SPPB PAT-D Leg Press	ActivPAL *
SECRET-II (Kitzman, WFU)	M / F	60 +	HFpEF	88	CR+AT vs CR+AT+FT 24 weeks		MRI DEXA *	Gait Speed SPPB *		CES-D *
SILVER (Beavers, WFU)	M / F	60 -79	Obesity	24	hypocaloric dietary intervention soy based meal replacemts vs animal protein based MR 3 months	Serum Muscle DNA	CT DEXA	Gait Speed Grip Strength SPPB ESPPB * Knee Extensor		MMSE
Skeletal MRI (Kitzman, WFU)	M / F	60 +	Exercise Intolerance, Heart failure, preserved ejection fraction	20	This study will enroll 20 participants. 10 participants will be 60 years and older, have been diagnosed with HFpEF, and suffer exercise intolerance. The remaining 10 participants will be in the age and sex matched control group. 4 weeks	Serum Plasma	MRI	Gait Speed Grip Strength SPPB Knee Extensor		CES-D *
START (Messier, WFU)	M / F	50 +	Arthritis	372	randomized trial 18 mos					MoCA *
SWALLOW (Butler, WFU)	M / F	18 -100	swallowing disorder	220			CT	Gait Speed Grip Strength SPPB PAT-D		DSST MMSE CES-D
TRAIN (Kritchevsky, WFU)	M / F	55 +	Heart Failure	294		Serum Plasma Urine	DEXA	Grip Strength SPPB PAT-D		CES-D
UNITS (Parker-Autry, WFU)	F	70 +	Urinary Incontinence	71	Interventional (Clinical Trial) Parallel Assignment	Urine	DEXA *	Gait Speed Grip Strength ESPPB PAT-D Knee Extensor Postural Sway		MoCA CES-D
UPLIFT (Houston, WFU)	M / F	65 -85	Obesity	187	Interventional (Clinical Trial) 18 mos		CT DEXA	Gait Speed Grip Strength SPPB * ESPPB Knee Extensor CHAMPS		DSST MoCA CES-D
Vitamin D Supplement (Houston, WFU)	M / F	70 -89	Vitamin D insufficient	26	4-month RCT Vitamin D + Calcium supplementation vs. calcium only	Serum Plasma Muscle	DEXA	Gait Speed Grip Strength SPPB PAT-D Leg Press Knee Extensor * Postural Sway *		DSST * MoCA * MMSE Story Recall * CES-D *
WALCS (McDermott, NW)	M / F	50 +	Peripheral artery disease	720	observational longitudinal cohort study N/A	Serum Plasma		Gait Speed SPPB		3MSE
WALCS II (McDermott, NW)	M / F	59 +	Peripheral artery disease	800	observational longitudinal cohort study N/A	Serum Plasma	CT	Gait Speed SPPB Leg Press	Fitbit	MMSE CES-D
Study (PI)	Gender	Age	Disease/ Condition	N=	Design / Intervention	Biospecimen	Imaging	Physical	Activity Monitoring	Cognitive / Depression

WHO CAN REGISTER STUDY META DATA:

OAIC-Affliated Centers are eligible to submit meta data related to their studies.

HOW TO GET STARTED:

Download PSR Instructions

Contact the Registry Coordinator at (336) 713-7126 or PepperCenter@WakeHealth.edu with further questions.